Targeted therapies for advanced thyroid cancer

Current Opinion in Oncology

Volumn 23, Issue 1, 2011, Pages 13-21

  Puxeddu, Efisio ^a,b   Romagnoli, Serena ^a,b   Dottorini, Massimo Eugenio ^b,c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Umbria Regional Cancer Network   (Italy)

^c Hospital of Perugia   (Italy)

Author keywords

Antiangiogenic drugs; Epigenetics; Targeted therapies; Thyroid cancer; Tyrosine kinase inhibitors

Indexed keywords

AXITINIB; B RAF KINASE; BORTEZOMIB; CARBOPLATIN; COMBRETASTATIN A4 PHOSPHATE; DEPSIPEPTIDE; E 7080; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; K RAS PROTEIN; MOTESANIB; PACLITAXEL; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLX 4032; PLX 4720; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; ROMIDEPSIN; ROSIGLITAZONE; SCATTER FACTOR; SELUMETINIB; SORAFENIB; TIPIFARNIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; VORINOSTAT; XL 184;

ADVANCED CANCER; ANAPLASTIC THYROID CARCINOMA; ANGIOGENESIS; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CARDIOTOXICITY; DIARRHEA; DIFFERENTIATED THYROID CARCINOMA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HEPATITIS; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MALABSORPTION; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NONHUMAN; ONCOGENE H RAS; ONCOGENE N RAS; PANCREATITIS; PHARMACOGENOMICS; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; SIDE EFFECT; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; UNSPECIFIED SIDE EFFECT;

HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS;

EID: 79851509982     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328340cf94     Document Type: Article

References (59)

1. Ward EM, Jemal A, Chen A. Increasing incidence of thyroid cancer: is diagnostic scrutiny the sole explanation? Future Oncol 2010; 6:185-188.
2. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167-1214.
3. Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 2007; 8:148-156. (Pubitemid 46158381)
4. 18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91:498-505. (Pubitemid 43236915)
5. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19:565-612.
6. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008; 68:3077-3080.
7. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438:967-974. (Pubitemid 43093963)
8. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008; 21:S37-S43. (Pubitemid 351592770)
9. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 2009; 69:4885-4893.
10. Puxeddu E, Fagin JA. Genetic markers in thyroid neoplasia. Endocrinol Metab Clin North Am 2001; 30:493-513. (Pubitemid 32606684)
11. Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008; 93:682-687. (Pubitemid 351398539)
12. Jones PA, Baylin SB. The fundamental role ofepigenetic events in cancer. Nat Rev Genet 2002; 3:415-428. (Pubitemid 34587077)
13. Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology 2007; 148:948-953.
14. Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 2009; 94:1493-1499.
15. Nemunaitis JJ, Senzer NN, Kurzrock R, et al. Phase I dose escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008; 26:14583.
16. Bible KC, Smallridge RC, Maples WJ, et al. Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers. J Clin Oncol 2009; 27:3521.
17. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165:35-52. (Pubitemid 38821812)
18. Matsui J, Funahashi Y, Uenaka T, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008; 14:5459-5465.
19. Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006; 66:8715-8721. (Pubitemid 44449188)
20. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007; 6:2012-2021. (Pubitemid 47052491)
21. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109. (Pubitemid 39331023)
22. Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006; 91:4070-4076. (Pubitemid 44536887)
23. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62:4645-4655.
24. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002; 62:7284-7290. (Pubitemid 36025251)
25. Cui JJ. Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications. Expert Opin Ther Pat 2007; 17:1035-1045. (Pubitemid 47610952)
26. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008; 26:4708-4713.
27. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Eng J Med 2008; 359:31-42. (Pubitemid 351931094)
28. Bible KC, Suman VJ, Molina JR, et al. Evidence of clinical efficacy of the multitargeted tyrosine kinase inhibitor pazopanib in rapidly progressive radio- iodine-refractory metastatic differentiated thyroid cancers: results of the phase 2 consortium study MC057H. In: 14th International Thyroid Congress; 11-16 September 2010; Paris; abstract OC-022.
29. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26:4714-4719.
30. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009; 27:1675-1684.
31. Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009; 161:923-931.
32. Cohen EE, Needles BM, Cullen KJ, et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 2008; 26:6025.
33. Leboulleux S, Bastholt L, Krause TM, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer (papillary or follicular; DTC): a randomized, double-blind phase II trial. In: 14th International Thyroid Congress; 11-16 September 2010; Paris; abstract OC-023.
34. Schlumberger M, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009; 27:3794-3801.
35. Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010; 28:2323-2330.
36. Busaidy NL, De Souza JA, Zimrin A, et al. Sunitinib in progressive metastatic medullary thyroid cancer. In: 14th International Thyroid Congress; 11 -16 September 2010; Paris; abstract OC-020.
37. Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010; 28:767-772.
38. Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95:2664-2671.
39. Wells SA, Robinson BG, Gagel RF, et al. Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind phase III trial (ZETA). J Clin Oncol 2010; 28:5503.
40. Kurzrock R, Cohen EE, Sherman SI, et al. Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. J Clin Oncol 2010; 28:5502.
41. Sherman SI,Tuttle RM, Ball DW, et al. NCCN practice guidelines in oncology: thyroid carcinoma. J Natl Compr Cancer Netw 2009; 1.
42. Cabanillas ME, Waguespack SG, Bronstein Y, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M.D. Anderson experience. J Clin Endocrinol Metab 2010; 95:2588-2595.
43. Brose MS, Troxel AB, Mamtani R. Phase II trial of everolimus with sorafenib for patients with differentiated thyroid cancer (DTC) who progress on sorafenib alone. J Clin Oncol 2010; 28:TS263.
44. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009; 15:2207-2214.
45. Torino F, Corsello SM, Longo R, et al. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009; 6:219-228.
46. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-819.
47. Leboeuf R, Baumgartner JE, Benezra M, et al. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab 2008; 93:2194-2201. (Pubitemid 351831535)
48. Lucas AS, Cohen EE, Cohen RB, et al. Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements. J Clin Oncol 2010; 28:5536.
49. Harvey RD, Kauh JS, Ramalingam SS, et al. Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer. J Clin Oncol 2010; 28:5589.
50. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140:209-221.
51. Hong DS, Sebti SM, Newman RA, et al. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res 2009; 15:7061-7068.
52. Gruning T, Tiepolt C, Zöphel K, et al. Retinoic acid for redifferentiation of thyroid cancer: does it hold its promise? Eur J Endocrinol 2003; 148:395-402. (Pubitemid 36527410)
53. Sherman EJ, Fury MG, Tuttle RM, et al. Phase II study ofdepsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma. J Clin Oncol 2009; 27:6059.
54. Piekarz R, Luchenko V, Draper D, et al. Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers. J Clin Oncol 2008; 26:3571.
55. Woyach JA, Kloos RT, Ringel MD, et al. Lack of therapeutic effect of the histone deacetylase inhibitorvorinostatin patients with metastaticradioiodine- refractory thyroid carcinoma. J Clin Endocrinol Metab 2009; 94:164-170.
56. Kebebew E, Lindsay S, Clark OH, et al. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. Thyroid 2009; 19:953-956.
57. MooneyCJ, Nagaiah G, Fu P, et al. A phase II trial offosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble in- tracellular adhesion molecule-1 with outcome. Thyroid 2009; 19:233-240.
58. Balkissoon J. Randomized phase 2/3 trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin and paclitaxel in anaplastic thyroid cancer: interim and safety efficacy results of the fact trial. In: 14th International Thyroid Congress; 11 -16 September 2010; Paris; abstract OC-024.
59. Chougnet C, Brassard M, Leboulleux S, et al. Molecular targeted therapies for patients with refractory thyroid cancer. Clin Oncol (R Coll Radiol) 2010; 22:448-455.